These hypotheses were addressed by studying the phenotype of circulating T cell subsets by flow cytometry and analysis of the gene expression, and by assessing CD4+ T cell reactivity to myelin basic protein (MBP) in untreated and natalizumab-treated MS patients. This evidence concerns the gene MBP and myeloid sarcoma.